6 Companies Hiring in Cambridge
Cambridge, Massachusetts remains a premier life‑sciences hub, anchored by giants like Intellia Therapeutics and Moderna and supported by the MassBio trade group. While BioSpace job postings fell 4% year‑over‑year in February, they surged 17% month‑over‑month, reflecting renewed hiring momentum. Six companies—AbbVie, Amgen, Intellia, Moderna, Regeneron and Takeda—are actively recruiting across research, clinical, manufacturing and regulatory functions. The openings range from AI/ML research scientists to senior directors in oncology and data dissemination, highlighting diverse talent needs.
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
Veristat announced an expansion of its regulatory and clinical‑trial services aimed at Chinese pharmaceutical and medical‑device companies seeking faster entry into European markets, as well as the United Kingdom, Switzerland, the United States, Canada and Australia. The CRO highlighted recent...
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive Β-Catenin:TCF Interaction, Receives FDA Orphan Drug Designation for...
Parabilis Medicines announced that the FDA has granted both Orphan Drug and Fast Track designations to zolucatetide, the first direct inhibitor of the β‑catenin:TCF interaction, for desmoid tumors. Early Phase 1/2 data showed a 100 % disease‑control rate in ten patients and...
Cell Rejuvenation Therapy to Hit Clinic
Life Biosciences has secured FDA IND approval for ER-100, the first partial epigenetic reprogramming therapy to enter human trials. The gene‑therapy delivers OCT‑4, SOX‑2 and KLF‑4 to retinal ganglion cells via a single intravitreal injection, aiming to reset age‑related epigenetic...
STAT+: Pharmalittle: We’re Reading About the FDA Warning Novo Nordisk, Lilly Investing in China, and More
Astellas Pharma leveraged the Trump administration’s push for lower U.S. drug prices to argue for higher reimbursement for its eye drug Izervay in Japan, winning a more generous price level. Meanwhile, a review of FDA adverse event reports found that...
FDA Adverse Event Monitoring System (AEMS) Electronic Submissions
The FDA is rolling out the Adverse Event Monitoring System (AEMS), replacing the legacy FAERS platform and consolidating reporting across drugs, biologics, devices, cosmetics, food, tobacco, and veterinary products. AEMS introduces standardized electronic submissions, AI‑driven redaction and analytics, and a...
Boron Chemistry Breaks Protein Synthesis Barrier, May Aid Cancer Therapies
Researchers at ETH Zurich have introduced a boron‑based ligation strategy that overcomes the concentration barrier in chemical protein synthesis. By masking potassium acyltrifluoroborates (KATs) with chiral zwitterionic complexes, the team achieved efficient peptide coupling at micromolar levels, far lower than...
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site
Chiesi Group and inhalation CDMO Bespak have expanded their long‑standing partnership by increasing pressurized metered‑dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel, UK site. The move supports Chiesi’s Carbon Minimal Inhaler (CMI) program, which targets up to a 90 %...
Scientists Found This Organism Can Survive Some of the Harshest Conditions in the Universe
Researchers at Johns Hopkins University demonstrated that the extremophile bacterium Deinococcus radiodurans can survive simulated asteroid‑impact pressures up to 2.4 gigapascals, with roughly 60% of cells remaining viable. The study identified the bacterium’s crystalline membrane protein arrangement and robust DNA‑repair...
Aplantex and Investissement Québec Team up to Produce Molecules for the Cosmetic and Food Industries
Aplantex has partnered with Investissement Québec to use its state‑of‑the‑art demonstration plant for green biotechnology extraction. The collaboration gives Aplantex access to advanced equipment and technical experts, enabling faster refinement of plant‑based molecules with antioxidant, anti‑inflammatory, antimicrobial and anti‑aging properties....
Vitamin D Triggers Autophagy, Improves Diabetes Metabolism
As a medical school professor, I teach students that vitamin D does far more than build bones. This new study shows just how much more. Researchers found that vitamin D supplementation significantly improved glucose tolerance, lowered fasting blood sugar, and reduced...
Biomarker for Differentiating MS From NMOSD Identified in Study
Researchers published in JAMA Neurology identified high‑level EBNA‑1 peptide antibody titers as a robust biomarker that distinguishes relapsing‑remitting multiple sclerosis from MOGAD and seronegative NMOSD. In a cohort of over 1,300 neuroinflammatory patients, persistent EBNA‑1 positivity in at least two...
Biotech Winter: Funding Freeze, IPO Surge, Path to Thaw
Biotech Science at Less Than Zero | Ep. 955 https://t.co/4DXKsaKXdO [00:49] Biotech capital winter deep dive [01:17] Scientific leaps vs frozen markets [02:31] The 2020–2021 biotech bubble [03:42] Crossover funds fuel IPO surge [04:56] Interest rates freeze biotech funding [07:58] Negative enterprise value phenomenon [10:37] Why Big Pharma...
DNA Repair Gene Changes Shape NSCLC Immune Landscape
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer https://t.co/mXZ80zYke3 #lcsm #ImmunoOnc #PrecisionMedicine @TempusAI https://t.co/UJwZnw4qnc
UCB Reports P-III (BE BOLD) Trial Results on Bimzelx (Bimekizumab) in Active Psoriatic Arthritis
UCB announced results from its Phase III BE BOLD trial comparing Bimzelx (bimekizumab) to risankizumab in 553 adults with active psoriatic arthritis. The study met its primary endpoint, showing Bimzelx superior in achieving ACR50 responses at week 16. Bimzelx is...
BRAF Class II/III Mutations Represent Unmet Clinical Need
Real-world clinical genomic analysis of Pts w/ BRAF mutated cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson et al #ESMO2240P @TempusLabs https://t.co/s5PEBEczlv @Annals_OncologyDOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx
Targeting Mitochondrial Redox Balance to Create Geroprotectors
Mitochondria and Aging: Redox Balance Modulation as a New Approach to the Development of Innovative Geroprotectors (Fundamental and Applied Aspects) https://t.co/TcG9GjMVg7 @IJMS_MDPI https://t.co/gxCC9SsO7z
Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic...
Genethon presented two‑year data from its dose‑escalation phase showing that GNT0004, administered at 3 × 10¹³ vg/kg, produced sustained functional gains and biomarker improvements in ambulatory DMD boys. Motor scores rose 9 points on the NSAA, the 6‑minute walk distance improved by...
Vima Raises $100M to Develop Oral Movement Disorder Drug
With $100M, Vima pursues an oral drug for movement disorders https://t.co/gLrhlYDMSy by @gwendolynawu #biotech #startups
Average-Onset CRC Shows Higher BRAF Mutation Rates
Genomic Landscapes of Early-Onset vs Average-Onset Colorectal Cancer Populations [Feb 28, 2025] Storandt et al. @Cancers_MDPI https://t.co/as7Jolal12 #crcsm #PrecisionMedicine most significant difference b/w eoCRC & aoCRC was higher rates of BRAF mutation among Pts w/ aoCRC https://t.co/7qB4b3A1WK
Zinereo Pharma Set to Rollout New Probiotic Solution for Childhood Ear Infections
Zinereo Pharma is preparing to launch Otibiome, a clinically evaluated probiotic derived from *Ligilactobacillus salivarius* PS7, aimed at preventing recurrent acute otitis media (AOM) in children. A pilot study of 61 kids showed an 84% drop in AOM episodes over...
New Nonprofit Secures $500M to Upgrade Science for AI
New nonprofit launches with at least $500 million to modernize scientific process for AI era https://t.co/yuypno6rVY via @ADeAngelis_bio
Playing Sound Waves to Cells Decreases Laryngeal Cancer Aggressiveness
An international team led by the Turku Bioscience Centre discovered that applying sound‑wave vibration to vocal‑fold cancer cells restores cellular movement and markedly reduces tumor aggressiveness. The mechanical stimulation lowered levels of the oncogenic protein YAP, both in cultured cells...
Scientists Are Trying to Train Lab-Grown Brains. The Brains Have Started to Solve Problems.
Scientists at UC Santa Cruz trained a mouse‑derived brain organoid to solve the classic cart‑pole balancing problem, boosting success from 4.5% with random stimulation to over 46% using adaptive electrical cues guided by an AI algorithm. The tiny, pepper‑corn‑sized tissue,...
Keytruda and Padcev Could Become Cancer’s Power Couple
Oncology is moving toward combination regimens, and Merck's Keytruda paired with Pfizer/Astellas' Padcev has emerged as a leading duo. A phase 3 trial in muscle‑invasive bladder cancer showed the combo cut the risk of recurrence, progression and death roughly in half,...
MIT Professor Hired by RFK Jr Fails Scientific Standards
The MIT professor who has been appointed by Robert F Kennedy Jr to review the safety of Covid-19 vaccines has failed to meet basic scientific standards in his own research on the topic, according to more than a dozen scientists...
Mortality Risk Similar with Tocilizumab, Rituximab in RA-ILD
An emulated target trial using the TriNetX database compared tocilizumab and rituximab in 1,194 rheumatoid arthritis‑associated interstitial lung disease (RA‑ILD) patients each over a five‑year follow‑up. The analysis found no statistically significant difference in all‑cause mortality (15.9% vs 17.7%) or...
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
Capricor Therapeutics announced that the FDA has scheduled an August 22 decision on its investigational Duchenne muscular dystrophy cell therapy, deramiocel, after lifting a prior complete response letter. The biotech resubmitted an enhanced package that includes robust Phase III HOPE‑3 data showing...
ARTHEx Biotech’s ATX-01 Secures the US FDA Fast Track Designation for Myotonic Dystrophy Type 1
ARTHEx Biotech announced that its RNA‑based drug ATX‑01 has received U.S. FDA Fast Track designation for treating Myotonic Dystrophy Type 1 (DM1). The therapy works by inhibiting miR‑23b, thereby increasing free MBNL protein, correcting splicing errors and reducing toxic DMPK mRNA...
UK Health Authorities Join Forces to Champion Foreign Infectious Disease Trials
UK health agencies and the Wellcome charity have launched a joint initiative to fund high‑quality infectious‑disease clinical trials in Africa, South Asia and Southeast Asia. The program, co‑led by the NIHR, the Foreign Commonwealth Development Office and Wellcome, will prioritize...
One-Time Pest Turned Eco-Warrior Degrades Polystyrene
Researchers from Harbin Institute of Technology and Stanford University found that the tropical cockroach Blaptica dubia can rapidly degrade polystyrene. In a 42‑day experiment, 50 roaches consumed about 6 mg of plastic per day, removing 54.9% of the material and achieving...
RA Capital, Forbion and Canaan Appear to Back Harbour's CTLA-4 Partner Solstice
RA Capital, Forbion, and Canaan have collectively invested in Solstice Therapeutics, the CTLA-4 antibody partner of Harbour Therapeutics. The funding round, reportedly a multi‑million dollar Series B, will support Solstice's pre‑clinical and early clinical programs. By backing Solstice, the investors...
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples
Eurofins Biomnis has developed and validated a new LC‑MS/MS method to detect and quantify cereulide toxin in human stool samples. The assay meets ISO 15189 requirements, accounting for matrix effects, and delivers turnaround times suitable for routine clinical labs. Cereulide, linked...
Viagra Compound May Hold Promise for Treating Fatal Genetic Disease
Researchers have identified the erectile‑dysfunction drug sildenafil as a potential therapy for Leigh syndrome, a fatal mitochondrial disorder affecting roughly one in 40,000 births. In cell models, the compound corrected mitochondrial membrane potential and normalized gene expression, while treated mice...
Early Data Show Benefits of GLP-1s in Breast Cancer
Early data presented at the San Antonio Breast Cancer Symposium indicate that GLP‑1 receptor agonists, long used for diabetes and obesity, are linked to markedly lower breast cancer recurrence and mortality. Retrospective analyses of thousands of patients showed up to...
Pharma Pulse: FDA Approval of Leucovorin Calcium for CFD and Persistent Inequities in OTC Naloxone Access
The FDA granted its first approval for a therapy targeting cerebral folate transport deficiency, an ultra‑rare neurological disorder, with Wellcovorin (leucovorin calcium) showing meaningful neurological improvements in 89% of patients. Meanwhile, over‑the‑counter naloxone prices have slipped by roughly $0.49 each...
NHS to Offer Fezolinetant for Menopause‑related Hot Flushes and Night‑sweats
NICE has issued final draft guidance recommending fezolinetant 45 mg once daily for moderate to severe menopause‑related vasomotor symptoms when hormone replacement therapy is unsuitable. The recommendation enables the drug to be supplied through the NHS, providing a new non‑hormonal option...
Arguing for PPARα Agonist Fenofibrate to Be Geroprotective
Researchers report that fenofibrate, a PPARα agonist approved for hyperlipidemia, extends lifespan and reverses cellular senescence in several mouse models, including D‑galactose‑induced, 18‑month‑old, and SAMP8 strains. The drug reduces age‑related lipid accumulation and restores mitochondrial function by up‑regulating CPT1C, a...
DNA Barcoding Reveals Which Gene-Therapy Nanoparticles Reach Targets in Vivo
Researchers at Oregon State University have developed a DNA‑based barcoding assay that measures, in living mice, which lipid nanoparticles successfully deliver gene‑editing cargo to target cellular compartments. The technique identified that many particles are degraded in lysosomes, while a newly...
Spinal Stimulation Above and Below Injury Restores Leg Movement and Sensory Feedback in Clinical Trial
Researchers at Brown University, Rhode Island Hospital, and VA Providence demonstrated that simultaneous electrical stimulation above and below a spinal cord lesion can restore both leg movement and spatial sensory feedback in people with complete spinal cord injuries. In a...
Antibiotics Can Affect the Gut Microbiome for Several Years, Study Shows
A new study published in Nature Medicine shows that a single course of antibiotics can alter the gut microbiome for up to eight years. Researchers linked Sweden’s national drug‑dispensing register with microbiome data from 14,979 adults, revealing lasting changes in...
When Ambition Meets Ambiguity: The Trends and Sentiments Shaping Biotech in 2026
ICON Biotech’s 2025 survey of 163 global biotech leaders, plus 100 Chinese executives, reveals shifting dynamics as China overtakes the United States in innovative trial volume and is projected to contribute 35% of FDA approvals by 2040. Funding remains scarce,...
Kainova Reports Positive Top Line Results From Phase I EPRAD Trial
Canada‑based Kainova Therapeutics announced positive top‑line results from its Phase I EPRAD study of DT‑9081, an oral EP4 receptor antagonist, in patients with advanced, recurrent and metastatic solid tumours. The trial, conducted at four sites in Belgium and France, met all...
ICEEL 2026: What Does It Mean to Be Human in the Age of Gene Editing?
The 3rd International Conference on the Ethics of Engineering Life (ICEEL 2026) will be held online March 23‑24, 2026, and is free to attend. Organized by the University of Basel, ETH Zurich, the Pontifical Academy for Life and Bambino Gesù Hospital,...
Intra‐Articular Injectable Hydrogel Microsphere‐Based Drug Delivery System for Osteoarthritis Treatment
Osteoarthritis incidence is climbing as populations age and obesity spreads, intensifying health and economic pressures. Conventional treatments merely decelerate disease progression and often entail systemic side effects or surgical risks. Emerging hydrogel microsphere platforms create a biomimetic joint microenvironment, offering...
GELITA and Black Drop Collaborate on GelMA Bioinks for 3D Bioprinting Research
GELITA and Black Drop have signed an R&D agreement to develop methacrylated gelatin (GelMA) bioinks for 3D bioprinting applications. The partnership will leverage GELITA’s ultra‑low endotoxin gelatin (MEDELLAPRO) and Black Drop’s custom bioprinting platforms to create clinically usable, scalable bioinks....
Grand Avenue Report Examines 2026 Life Sciences Readiness
Grand Avenue Software has published its 2026 Life Sciences Quality, Compliance & Operations Benchmark Report, drawing on hundreds of responses from QA, regulatory affairs and manufacturing professionals. The study reveals wide variation in FDA QMSR readiness, persistent quality improvement hurdles,...
Out-Of-Pocket’s 2025 Predictions | Out-Of-Pocket
Out‑Of‑Pocket’s 2025 outlook forecasts a turning point for several health‑care segments. Obesity drugs such as GLP‑1s are expected to become cost‑effective as pricing pressure and outcomes‑based contracts expand access. AI models will split, with healthcare‑specific versions emphasizing explainability, security and...
Melt&Marble Cleared to Sell Animal-Free ‘Designer Fats’ for Food & Personal Care
Swedish precision‑fermentation startup Melt&Marble has obtained regulatory clearance to commercialise its animal‑free “designer fats.” The MeltyMarble fat received US Generally Recognized as Safe status, while its Marble7 lipid earned an INCI name for worldwide personal‑care use. Backed by an $8.5 million...
Editing Away Autoimmunity at the HLA Source
In this episode, Daniel Levine interviews Richard Freed, CEO of Rheumagen, about the pivotal role of HLA genes in autoimmune diseases and the company’s innovative gene‑editing approach to cure them. Freed explains how a single amino‑acid change at a conserved...